Michael Hill
DPhil
Laboratory Scientific Director
Associate Professor Mike Hill joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2009 and is the Laboratory Scientific Director of the Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease.
He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within Oxford Population Health. Mike works closely with the department's principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. The Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Mike gained his DPhil at the University of Oxford in 1992 and continued his postdoctoral studies at the Nuffield Department of Clinical Medicine, Oxford and the Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Recent publications
Burden and Correlates of Multiple Chronic Infections and Their Associations With Cancer Incidence in Chinese Adults: A Large Case-Cohort Study.
Journal article
Yang L. et al, (2026), Int J Cancer
Associations of 6600 SomaScan proteins with demographic, lifestyle, environmental and health characteristics in Chinese adults.
Journal article
Chan KH. et al, (2026), Sci Rep
Effects of Sacubitril/Valsartan vs Irbesartan on Urine Tubular Biomarkers in CKD: Findings from the UK HARP-III Trial.
Journal article
Goonasekera MA. et al, (2026), Am J Nephrol, 1 - 9
Effects of vitamin D on biochemical markers of osteoporosis: A meta-analysis of randomised trials.
Journal article
Sandford Alber C. et al, (2026), Br J Nutr, 1 - 22
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
Journal article
Malijan GB. et al, (2026), Am J Kidney Dis, 87, 553 - 563.e1
